Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where J. Aupetit is active.

Publication


Featured researches published by J. Aupetit.


Proceedings of the National Academy of Sciences of the United States of America | 2012

Heptahelical protein PQLC2 is a lysosomal cationic amino acid exporter underlying the action of cysteamine in cystinosis therapy

Adrien Jézégou; Elisa Llinares; Christine Anne; Sylvie Kieffer-Jaquinod; Seana O’Regan; J. Aupetit; Allel Chabli; Corinne Sagné; Cécile Debacker; Bernadette Chadefaux-Vekemans; Agnès Journet; Bruno André; Bruno Gasnier

Cystinosin, the lysosomal cystine exporter defective in cystinosis, is the founding member of a family of heptahelical membrane proteins related to bacteriorhodopsin and characterized by a duplicated motif termed the PQ loop. PQ-loop proteins are more frequent in eukaryotes than in prokaryotes; except for cystinosin, their molecular function remains elusive. In this study, we report that three yeast PQ-loop proteins of unknown function, Ypq1, Ypq2, and Ypq3, localize to the vacuolar membrane and are involved in homeostasis of cationic amino acids (CAAs). We also show that PQLC2, a mammalian PQ-loop protein closely related to yeast Ypq proteins, localizes to lysosomes and catalyzes a robust, electrogenic transport that is selective for CAAs and strongly activated at low extracytosolic pH. Heterologous expression of PQLC2 at the yeast vacuole rescues the resistance phenotype of an ypq2 mutant to canavanine, a toxic analog of arginine efficiently transported by PQLC2. Finally, PQLC2 transports a lysine-like mixed disulfide that serves as a chemical intermediate in cysteamine therapy of cystinosis, and PQLC2 gene silencing trapped this intermediate in cystinotic cells. We conclude that PQLC2 and Ypq1–3 proteins are lysosomal/vacuolar exporters of CAAs and suggest that small-molecule transport is a conserved feature of the PQ-loop protein family, in agreement with its distant similarity to SWEET sugar transporters and to the mitochondrial pyruvate carrier. The elucidation of PQLC2 function may help improve cysteamine therapy. It may also clarify the origin of CAA abnormalities in Batten disease.


Human Mutation | 2009

Structural insights on pathogenic effects of novel mutations causing pyruvate carboxylase deficiency.

Sophie Monnot; Valérie Serre; Bernadette Chadefaux-Vekemans; J. Aupetit; S. Romano; Pascale de Lonlay; Jean‐Marie Rival; Arnold Munnich; Julie Steffann; Jean-Paul Bonnefont

Pyruvate carboxylase (PC), a key enzyme for gluconeogenesis and anaplerotic pathways, consists of four domains, namely, biotin carboxylase (BC), carboxyltransferase (CT), pyruvate carboxylase tetramerization (PT), and biotin carboxyl carrier protein (BCCP). PC deficiency is a rare metabolic disorder inherited in an autosomal recessive way. The most severe form (form B) is characterized by neonatal lethal lactic acidosis, whereas patients with form A suffer chronic lactic acidosis with psychomotor retardation. Diagnosis of PC deficiency relies on enzymatic assay and identification of the PC gene mutations. To date, six mutations of the PC gene have been identified. We report nine novel mutations of the PC gene, in five unrelated patients: three being affected with form B, and the others with form A. Three of them were frameshift mutations predicted to introduce a premature termination codon, the remaining ones being five nucleotide substitutions and one in frame deletion. Impact of these mutations on mRNA was assessed by RT‐PCR. Evidence for a deleterious effect of the missense mutations was achieved using protein alignments and three‐dimensional structural prediction, thanks to our modeling of the human PC structure. Altogether, our data and those previously reported indicate that form B is consistently associated with at least one truncating mutation, mostly lying in CT (C‐terminal part) or BCCP domains, whereas form A always results from association of two missense mutations located in BC or CT (N‐terminal part) domains. Finally, although most PC mutations are suggested to interfere with biotin metabolism, none of the PC‐deficient patients was biotin‐responsive. Hum Mutat 0:1–7, 2009.


Journal of Neurochemistry | 2004

The neuronal SAPK/JNK pathway is altered in a murine model of hyperhomocysteinemia

Karine Robert; Dominique Santiard-Baron; Jean-François Chassé; Evelyne Paly; J. Aupetit; P. Kamoun; Jacqueline London; Nathalie Janel

Deficiency in cystathionine beta synthase (CBS) leads to high plasma homocysteine concentrations and causes hyperhomocysteinemia, a common risk factor for vascular disease, stroke and possibly neurodegenerative diseases. Various neuronal diseases have been associated with hyperhomocysteinemia, but the molecular mechanisms of homocysteine toxicity are unknown. We investigated the pathways involved in the pathological process, by analyzing differential gene expression in neuronal tissues. We used a combination of differential display and cDNA arrays to identify genes differentially expressed during hyperhomocysteinemia in brain of CBS‐deficient mice. In this murine model of hyperhomocysteinemia, both plasma and brain homocysteine concentrations were high. Several genes were found to be differentially expressed in the brains of CBS‐deficient mice, and the identities of some of these genes suggested that the SAPK/JNK pathway was altered in the brains of CBS‐deficient mice. We therefore investigated the activation of proteins involved in the SAPK/JNK cascade. JNK and c‐Jun were activated in the hippocampal neurones of CBS‐deficient mice, suggesting that the SAPK/JNK pathway may play an important role in the development of neuronal defects associated with hyperhomocysteinemia.


Prenatal Diagnosis | 1996

GESTATIONAL AGE‐RELATED REFERENCE VALUES FOR AMNIOTIC FLUID AMINO ACIDS: A USEFUL TOOL FOR PRENATAL DIAGNOSIS OF AMINOACIDOPATHIES

D. Rabier; Bernadette Chadefaux-Vekemans; J. F. Oury; J. Aupetit; J. Bardet; M. Gasquet; E. Merhand; P. Parvy; P. Kamoun

In this study we have measured the concentration of 24 amino acids and total homocysteine in amniotic fluids obtained between the tenth and 32nd week of gestation from pregnancies not at risk for metabolic diseases. These results are used as reference values to which are compared values obtained from pregnancies at risk for citrullinaemia, argininosuccinic aciduria, HHH (hyperornithinaemia, hyperammonaemia and homocitrullinaemia) syndrome, cobalamin metabolism disorders (CblC or CblD), and sulphite oxidase deficiency. We discuss the helpfulness of amino acid analysis in amniotic fluid for prenatal diagnosis of aminoacidopathies.


Neuroscience Research | 2005

Plasma homocysteine levels are not increased in murine models of Alzheimer's disease

Dominique Santiard-Baron; J. Aupetit; Nathalie Janel

Alzheimers disease (AD) patients tend to have increased plasma levels of homocysteine. However, it is unclear whether abnormality in homocysteine levels is a primary cause of Alzheimers disease or a disease marker. In order to investigate the relative impact of Alzheimers disease on plasma homocysteine levels, total plasma homocysteine levels were evaluated in transgenic mouse models that exhibit abnormalities in their brains that are similar to Alzheimers patients. No significant difference was observed in blood of murine models compared to control mice, indicating that elevated plasma homocysteine level seems to be a risk marker at the most.


Prenatal Diagnosis | 2009

Gestational age-related reference values for amniotic fluid organic acids.

Chris Ottolenghi; N. Abermil; A. Lescoat; J. Aupetit; O. Beaugendre; Nicole Morichon-Delvallez; D. Ricquier; Bernadette Chadefaux-Vekemans; D. Rabier

Normative data for amniotic fluid (AF) levels of organic acids at different gestational ages are lacking. They can provide a useful framework to investigate the accuracy of prenatal diagnosis for organic acidemias.


Nephrology Dialysis Transplantation | 1999

Sustained reduction of hyperhomocysteinaemia with folic acid supplementation in predialysis patients

Paul Jungers; Dominique Joly; Ziad A. Massy; Philippe Chauveau; Anh-Thu Nguyen; J. Aupetit; Bernadette Chadefaux


Journal of Biological Chemistry | 2003

Altered gene expression in liver from a murine model of hyperhomocysteinemia.

Karine Robert; Jean-François Chassé; Dominique Santiard-Baron; Catherine Vayssettes; Allel Chabli; J. Aupetit; Nobuyo Maeda; P. Kamoun; Jacqueline London; Nathalie Janel


Clinical Biochemistry | 2007

Measurement of cystine in granulocytes using liquid chromatography-tandem mass spectrometry

Allel Chabli; J. Aupetit; M. Raehm; D. Ricquier; Bernadette Chadefaux-Vekemans


Neuromuscular Disorders | 2000

Genotype/phenotype correlation in carnitine palmitoyl transferase II deficiency: lessons from a compound heterozygous patient.

L. Thuillier; C. Sevin; F. Demaugre; M. Brivet; D. Rabier; Véronique Droin; J. Aupetit; N. Abadi; P. Kamoun; J. M. Saudubray; Jean-Paul Bonnefont

Collaboration


Dive into the J. Aupetit's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Allel Chabli

Necker-Enfants Malades Hospital

View shared research outputs
Top Co-Authors

Avatar

D. Rabier

Necker-Enfants Malades Hospital

View shared research outputs
Top Co-Authors

Avatar

P. Kamoun

Necker-Enfants Malades Hospital

View shared research outputs
Top Co-Authors

Avatar

Jean-Paul Bonnefont

Necker-Enfants Malades Hospital

View shared research outputs
Top Co-Authors

Avatar

Bernadette Chadefaux

Necker-Enfants Malades Hospital

View shared research outputs
Top Co-Authors

Avatar

D. Ricquier

Necker-Enfants Malades Hospital

View shared research outputs
Top Co-Authors

Avatar

J. Bardet

Necker-Enfants Malades Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge